Question 1

What is precision oncology?

Accepted Answer

Precision oncology is a medical approach that targets the specific genetic mutation driving a patient's cancer, rather than applying a broad-spectrum treatment. Instead of a generalised therapy, it delivers a targeted one — matched to the molecular profile of the tumour. The approach has been gaining momentum as clinical trials, including a landmark Phase 3 result in pancreatic cancer, demonstrate meaningfully improved patient outcomes.

Question 2

What is synthetic lethality in cancer treatment?

Accepted Answer

Synthetic lethality is a strategy that targets two simultaneous weaknesses in a cancer cell. Either vulnerability alone would not destroy the cell, but attacking both at once causes it to collapse — while leaving healthy cells largely unharmed. It is considered a cleaner, more targeted alternative to traditional chemotherapy, and is central to the scientific approach of IDEAYA Biosciences (IDYA).

Question 3

What is CRISPR and how is it used in oncology?

Accepted Answer

CRISPR is a gene-editing technology that allows researchers to make highly precise changes to DNA. In oncology, companies like Repare Therapeutics (RPTX) use a CRISPR-enabled platform to identify and exploit the genetic errors that cause tumours to grow. It is a high-ambition, high-risk approach that sits at the cutting edge of precision cancer medicine.

Question 4

Is precision oncology a good investment?

Accepted Answer

Precision oncology offers significant growth potential, but it comes with real risk. Most companies in the space are clinical-stage — meaning they are still running trials and are not yet generating revenue from approved products. A failed trial can erase substantial value quickly, whilst a successful Phase 3 result, as seen with Revolution Medicines, can do the opposite. Investors should treat this as a tactical, growth-focused allocation within a diversified portfolio. All investments carry risk and you may lose money.

Question 5

Top precision oncology stocks to watch?

Accepted Answer

The three lead companies in Nemo's Precision Oncology theme are IDEAYA Biosciences (IDYA), SpringWorks Therapeutics (SWTX), and Repare Therapeutics (RPTX). Each approaches the opportunity from a distinct scientific angle — synthetic lethality, targeted solid tumour therapy, and CRISPR-enabled genomic research respectively. They were selected for their direct scientific connection to precision oncology, not simply because they carry a biotech label.

Question 6

How risky are clinical-stage biotech stocks?

Accepted Answer

Clinical-stage biotech stocks are among the most volatile in the market. These companies are spending capital to generate trial data, and that data determines almost everything. A single failed trial can wipe significant value from a stock within hours, whilst a successful Phase 3 result can drive sharp gains just as rapidly. The volatility is structural and should be understood clearly before investing. All investments carry risk and you may lose money.

Question 7

How much money do I need to invest in precision oncology stocks?

Accepted Answer

Through Nemo, you can start investing in precision oncology stocks with as little as $1, thanks to fractional shares. This means you do not need to purchase a full share of any company to gain exposure to the theme — making it accessible for beginner investors and those building a portfolio gradually.

Question 8

Why did Revolution Medicines' stock rise 40% overnight?

Accepted Answer

Revolution Medicines reported Phase 3 clinical trial results showing that its treatment nearly doubled survival rates for patients with metastatic pancreatic cancer — one of the hardest-to-treat cancers in oncology. That level of clinical success is rare in this disease area, and the result validated the broader precision oncology model, triggering a surge of nearly 40% in Revolution Medicines' stock in a single trading session.

Question 9

Is now a good time to invest in precision oncology?

Accepted Answer

The Revolution Medicines Phase 3 result has renewed institutional interest in the precision oncology sector, and historically, high-profile clinical breakthroughs have triggered waves of funding across related companies. However, timing a clinical-stage biotech theme is genuinely difficult. Nemo's research notes that the current catalyst — a near-doubling of survival rates in pancreatic cancer — is significant, but forward-looking statements carry inherent uncertainty.

Question 10

What is driving growth in the precision oncology market?

Accepted Answer

The shift from generalised to personalised cancer care has been building for over a decade, but the pace has recently accelerated. Gene-editing platforms, synthetic lethality strategies, targeted biologics, and precision diagnostics are no longer theoretical — they are generating Phase 3 data and approaching commercialisation. High-profile clinical successes, like the Revolution Medicines pancreatic cancer trial, are reinforcing confidence in the model across the medical and investment community.

Question 11

What is Nemo and how does it work?

Accepted Answer

Nemo is an ADGM-regulated thematic investment platform offering commission-free trading in curated portfolios of US stocks and ETFs. It provides AI-powered research tools, analyst ratings, and fractional shares starting from just $1 — making it accessible for investors across Africa and beyond. The Precision Oncology theme is available directly on the platform, with key data points and analyst insights available on the theme landing page.

Question 12

Can I invest in precision oncology from Africa?

Accepted Answer

Yes. Nemo is designed to give investors across Africa access to high-conviction thematic investment opportunities, including precision oncology stocks. With fractional shares starting from $1, commission-free trading, and AI-powered research tools, Nemo removes many of the traditional barriers to accessing US-listed biotech stocks from outside of major financial centres.

When One Cancer Drug Changes Everything: The Precision Oncology Opportunity

When One Cancer Drug Changes Everything: The Precision Oncology Opportunity

The Billion-Dollar Clinical Trial Shockwave

Precision Oncology: The High-Stakes Science That Could Reshape Portfolios

Scalpels Instead of Sledgehammers

The Billion-Dollar Clinical Trial Shockwave

Precision Oncology: The High-Stakes Science That Could Reshape Portfolios

Scalpels Instead of Sledgehammers

The Clinical Gladiators

The Brutal Reality of Biotech

The Final Verdict

Deep Dive

Market & Opportunity

Key Companies

Primary Risk Factors

Growth Catalysts

최신 인사이트

Why ASML's Bulging Backlog Is a Chip Supercycle Tell

Waymo Crosses The Border Into Driverless Territory

Why a $6.3bn Deal Just Reshaped Data Security

Why Boeing's Delivery Logjam Could Finally Break

Neutron's Slip to 2027 Puts Rocket Lab's Growth Story to the Test

이 기회에 투자하는 방법

자주 묻는 질문

최신 인사이트

Why ASML's Bulging Backlog Is a Chip Supercycle Tell

Waymo Crosses The Border Into Driverless Territory

Why a $6.3bn Deal Just Reshaped Data Security

Why Boeing's Delivery Logjam Could Finally Break

Neutron's Slip to 2027 Puts Rocket Lab's Growth Story to the Test

Why ASML's Bulging Backlog Is a Chip Supercycle Tell

Waymo Crosses The Border Into Driverless Territory

Why a $6.3bn Deal Just Reshaped Data Security

Why Boeing's Delivery Logjam Could Finally Break

Neutron's Slip to 2027 Puts Rocket Lab's Growth Story to the Test